Biogen (BIIB) Income towards Parent Company (2009 - 2026)

Biogen (BIIB) posted quarterly Income towards Parent Company of $319.5 million for Q1 2026, up 32.85% year-over-year from $240.5 million in Q1 2025, and up 753.37% on a QoQ basis from -$48.9 million in Q4 2025.

Biogen (BIIB) Income towards Parent Company (2009 - 2026) Analysis & Trends

Biogen (BIIB) has reported Income towards Parent Company for 18 consecutive years, with $319.5 million the latest figure, recorded in Q1 2026.

  • In Q1 2026, Income towards Parent Company rose 32.85% year-over-year to $319.5 million; the TTM figure through Mar 2026 stood at $1.4 billion (down 7.26% YoY), while the FY2025 annual figure was $1.3 billion, down 20.79% from the prior year.
  • Income towards Parent Company came in at $319.5 million for Q1 2026 at Biogen, up from -$48.9 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $1.1 billion in Q3 2022, with the low at -$64.2 million in Q3 2023.
  • Average Income towards Parent Company over 5 years is $437.3 million, with a median of $393.4 million recorded in 2024.
  • Across the five-year window, Income towards Parent Company surged 948.37% in 2022 and plunged 118.34% in 2025, its largest moves.
  • Year by year, Income towards Parent Company stood at $559.0 million in 2022, then sank by 55.47% to $248.9 million in 2023, then increased by 7.15% to $266.7 million in 2024, then slumped by 118.34% to -$48.9 million in 2025, then surged by 753.37% to $319.5 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered $319.5 million, -$48.9 million, and $466.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 319.50 Mn
Dec 31, 2025 -48.90 Mn
Sep 30, 2025 466.50 Mn
Jun 30, 2025 634.80 Mn
Mar 31, 2025 240.50 Mn
Dec 31, 2024 266.70 Mn
Sep 30, 2024 388.50 Mn
Jun 30, 2024 583.60 Mn
Mar 31, 2024 393.40 Mn
Dec 31, 2023 248.90 Mn
Sep 30, 2023 -64.20 Mn
Jun 30, 2023 599.70 Mn
Mar 31, 2023 397.20 Mn
Dec 31, 2022 559.00 Mn
Sep 30, 2022 1.14 Bn
Jun 30, 2022 1.06 Bn
Mar 31, 2022 243.40 Mn
Dec 31, 2021 -101.70 Mn
Sep 30, 2021 -134.80 Mn
Jun 30, 2021 528.30 Mn